Aspireo Pharmaceuticals Limited Report issue

For profit Phase 2
Founded: Tel Aviv Israel (2010)
Status: Defunct (2015)

Organization Overview

First Clinical Trial
2010
NCT02217488
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

octreotide (sandostatin) (4 trials)

sodium chloride (3 trials)

somatoprim (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acromegaly (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3